Luke O'Neill
Director/Board Member bij POOLBEG PHARMA PLC
Profiel
Luke O'Neill is the founder of Inflazome Ltd.
(2016) where he holds the title of Director & Chief Scientific Officer.
He is also the founder of Sitryx Therapeutics Ltd.
Dr. O'Neill's current job(s) include Independent Non-Executive Director at Poolbeg Pharma Plc, Member at European Molecular Biology Organization, Member at Royal Irish Academy, and Professor at Trinity Biomedical Sciences Institute.
Dr. O'Neill's former job(s) include Director & Chief Scientific Officer at Senda Biosciences, Inc. and Professor at Trinity College Dublin.
Dr. O'Neill received a doctorate degree from the University of London.
Actieve functies van Luke O'Neill
| Bedrijven | Functie | Begin |
|---|---|---|
| POOLBEG PHARMA PLC | Director/Board Member | - |
| European Molecular Biology Organization | Corporate Officer/Principal | 01-01-2005 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Founder | 01-01-2016 |
| Trinity Biomedical Sciences Institute | Corporate Officer/Principal | - |
| Royal Irish Academy | Corporate Officer/Principal | - |
Eerdere bekende functies van Luke O'Neill
| Bedrijven | Functie | Einde |
|---|---|---|
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Founder | - |
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
| Trinity College Dublin | Corporate Officer/Principal | - |
Opleiding van Luke O'Neill
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| POOLBEG PHARMA PLC | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
| European Molecular Biology Organization | |
| Trinity Biomedical Sciences Institute | |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
